PHILADELPHIA, September 29 – Premier Research Group Limited, an international CRO with unrivaled analgesia research expertise, recently contributed to the 13th World Congress on Pain. Dr. Stephen Daniels, Executive Medical Director, co-authored six posters presented at the meeting.
Dr. Stephen Daniels, a prolific investigator in acute pain studies, has served as Principal Investigator on more than 200 clinical trials in acute and chronic pain and general medicine as well as providing client consultation regarding the design and implementation of acute pain trials. Over his 17 year career, he has served as author/co-author on numerous posters, abstracts and manuscripts in the area of analgesia including postoperative pain and dysmenorrhea.
The posters, available on the company website, include:
• Comparison of the Analgesic Efficacy of Concurrent Ibuprofen and Paracetamol with Ibuprofen or Paracetamol Alone in the Management of Moderate-to-Severe Postoperative Dental Pain
• Safety and Efficacy of Dyloject®, A Novel Parenteral Diclofenac Formulation, after Orthopedic Surgery: Superiority over Ketorolac for Analgesia and Opioid-Sparing
• A Single-Tablet Combination of Ibuprofen/Paracetamol in the Management of Moderate to Severe Postoperative Dental Pain: A Multicenter, Two-Stage, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Factorial Study
• A Pooled Analysis Evaluating the Efficacy of Etoricoxib in Postoperative Dental Pain
• Evaluation of the Dose Range of Etoricoxib in an Acute Pain Setting Using the Postoperative Dental Pain Model
• A Comparison of the Analgesic Efficacy and Tolerability of a Combination of Ibuprofen 400 mg plus Paracetamol 1000 mg, a Combination of Ibuprofen 200 mg plus Paracetamol 500 mg, a Combination of Ibuprofen 400 mg plus Codeine 25.6 mg, a Combination of Paracetamol 1000 mg plus Codeine 30 mg, and Placebo in Postoperative Dental Pain Following Third Molar Extraction
The results of a seventh study conducted by Premier Research regarding ibuprofen effervescent tablets were also presented.
In addition to the full service CRO offerings, Premier Research owns and operates three clinical research centers in Austin, TX, Salt Lake City, UT and Peoria, AZ designed to offer clinical site services from Phase 1 POC trials to Phase 4 post-marketing trials primarily in the areas of analgesia, rheumatology, neuroscience and oncology. Premier Research has conducted more than 350 pain and arthritis studies involving mechanistically-novel pharmacologic agents as well as innovative formulation and drug delivery systems for analgesics.
Premier Research works with companies from early stages of clinical plan development through full clinical development programs and regulatory submissions for their compounds. Since Premier Research has helped pioneer the development of new research models and new pain assessment methodologies, the company helps drug developers identify appropriate endpoints, study design, and the overall clinical plan for their products.
In addition, the company offers unparalleled support with pediatric pain research and assistance with PREA commitments and BPCA written requests. This includes development of pediatric plans and protocols, waiver requests, study feasibility and expertise with respect to the FDA Pediatric Review Committee (PeRC).
About Premier Research
Premier Research is a leading global solutions-driven CRO committed to therapeutic focus and operational expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. With a network of skilled staff operating across North America and Europe and partnerships in Latin America, Asia, South Africa, Australia and the Middle East, Premier Research manages Phase 1-4 trials and programs.
They are leaders in clinical research for analgesia, oncology, neuroscience, and cardiovascular and have a wealth of experience in medical device and pediatric research. They offer a comprehensive selection of services for every phase of clinical development including, regulatory affairs, clinical trial management, clinical research centers, medical affairs and strategic consulting, pharmacovigilance, data operations, biostatistics, medical writing, IVRS/IWRS, quality assurance, and functional sourcing.
www.premier-research.com
For further information, please contact:
Jessica Barag jessica.barag@premier-research.com (215) 282-5391
